Development and validation of an rp-hplc method for simultaneous determination of Ramipril and Amlodipine in tablets

An rp-hplc method for the simultaneous determination of Ramipril (RP) and Amlodipine (AL) in tablets was developed and validated by Chinese Pharmacopoeia 2010. The linearity of the proposed method was investigated in the range of 0.01–0.25 mg/mL (r(2)=0.9998) for RP and 0.014–0.36 mg/mL (r(2)=0.9997...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Shi-Ying, Qiu, Shi-Ting, Wu, Wei, Fu, Chun-Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Xi'an Jiaotong University 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5761019/
https://www.ncbi.nlm.nih.gov/pubmed/29403852
http://dx.doi.org/10.1016/j.jpha.2013.09.002
Descripción
Sumario:An rp-hplc method for the simultaneous determination of Ramipril (RP) and Amlodipine (AL) in tablets was developed and validated by Chinese Pharmacopoeia 2010. The linearity of the proposed method was investigated in the range of 0.01–0.25 mg/mL (r(2)=0.9998) for RP and 0.014–0.36 mg/mL (r(2)=0.9997) for AL. The limits of detection (LOD) were 0.06 μg/mL and 0.02 μg/mL for RP and AL, and the limits of quantitation (LOQ) were 0.2 μg/mL and 0.07 μg/mL, respectively. Some major impurities and degradation products did not disturb the detection of RP and AL and the assay can thus be considered stability-indicating.

Ejemplares similares